15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Nautilus Biotechnology Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $4.00 to $4.00, so the covering firms are broadly aligned. The average target of $4.00 sits 257% above the current $1.12. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.52 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Nautilus Biotechnology Inc.
As of Sep, 2 of 2 firms rate NAUT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NAUT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.11 – $-0.11 · 1 analysts · +0% YoY
Next period, 1 analysts expect Nautilus Biotechnology Inc to earn $-0.11 a share (range $-0.11 – $-0.11), versus $-0.11 a year earlier. Full-year consensus is $-0.51, growing to $-0.52 the year after.
REVENUE · NEXT QUARTER
$200.0K
Range $200.0K – $200.0K · 1 analysts
Revenue is expected to reach $200.0K (range $200.0K – $200.0K). Full-year consensus is $500.0K, rising to $6.1M next year.
Top analysts covering Nautilus Biotechnology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NAUT.
#1
Matthew Sykes
Goldman Sachs · Rank #274
Sell
$1.75+56.2% to target
Overall win rate
38%
+ Follow
#2
Subbu Nambi
Guggenheim
Buy
$4.00+257.1% to target
Coverage
—
+ Follow
#3
Puneet Souda
Leerink Partners
Buy
$4.00+257.1% to target
Coverage
—
+ Follow
#4
Daniel Brennan
TD Cowen
Buy
No targeton NAUT
Coverage
—
+ Follow
NAUT stock forecast FAQ
What is NAUT's average 12-month price target?+
The 2 analysts with a live target average $4.00 for Nautilus Biotechnology Inc over the next 12 months, ranging from a $4.00 high to a $4.00 low.
Is NAUT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover NAUT?+
2 analysts have an active rating on Nautilus Biotechnology Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NAUT?+
Among analysts who currently cover NAUT, Matthew Sykes of Goldman Sachs has the strongest overall Quantellect track record (Rank #274). Their current call is Sell with a $1.75 target.
What is Nautilus Biotechnology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.11 – $-0.11) across 1 analysts. Full-year EPS is projected at $-0.51, rising to $-0.52 the following year.
How much revenue is Nautilus Biotechnology Inc expected to report next quarter?+
Consensus revenue is $200.0K (range $200.0K – $200.0K). Full-year revenue is projected at $500.0K, growing to $6.1M next year.
Have analysts been upgrading or downgrading NAUT lately?+
As of Sep, 2 of 2 firms rate NAUT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NAUT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
